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Background: The ATPIII recommendations for patients with hypertriglyceridemia (HTG) are first to lower the low-density lipoprotein cholesterol 
(LDL-C) levels and then triglycerides (TG) in order to reduce cardiovascular (CV) risk. Some patients with HTG did not exhibit elevated LDL-C but 
represents a group with an increased CV risk. Statins have been shown convincingly to reduce cardiovascular morbidity and mortality in multiple 
large outcomes trials in various populations with substantial reductions in LDL-C and TG levels in non-diabetic and diabetic patients. The primary 
objective was to evaluate the efficacy of rosuvastatin in reducing TG levels in HTG Mexican patients from baseline to week 8.
Methods: This was a randomized, double blind, parallel group, placebo control, study. Patients entered a 5-week lead-in period, after which eligible 
patients (≥18 years, with TG ≥200, ≤800 mg/dl, statin naive, and without statin contraindication), were randomized to receive treatment with 
either rosuvastatin 10 (Group 1 (G1)) or 20 mg/day (G2) or placebo (G3) once daily for 8 weeks to evaluate the effects on triglycerides levels in 
hypertriglydemic patients.
Results: 335 patients were randomized; we show preliminary result of 270 patients (G1:90; G2: 95 and G3: 85). 138 women, mean age of 53±12 
years old; median (Md) body mass index of 29.29 (interquartile range (IR) 26.63 - 32.35). DM2 patients were 36 (13.3%) and with hypertension 
84 (31.1%). At baseline G1-3 Md laboratory values were: TG: 278, 268, 281 mg/dl (Kruskal Wallis (KW) p=0.47); LDL-C: 128, 129, 127 mg/dl 
(p=0.77); HDL-C 33, 34, 31 mg/dl (p=0.15); glucose: 97, 97, 95 mg/dl (p=0.14); CRP 3.1, 3.1, 3.1 mg/L (p=0.94). At eight weeks of treatment the 
Md percentage reduction of G 1-3 was: TG 26%, 33% and 8% (KW p=0.0001), (U Man Whitney (UM) G1-2 p=0.08, G1-3 P=0.002, G2-3 P=0.0001); 
LDL-C: 35%, 44% and -4% (p=0.001) (G1-2 P=0.0001, G1-3 P=0.0001, G2-3 p=0.0001). And the Md percentage increment of HDL cholesterol G1-3 
was 12%,7%,0% (p=0.03) (G1-2 p=0.14, G1-3 p=0.015, G2-3 p=0.14). No serious adverse event was observed.
Conclusions: In this trial of HTG Mexican patients, rosuvastatin significantly reduce TG levels and improve the atherogenic lipid profile.
